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Abstract 24	  
In striated muscle, EPA and DHA have differential effects on the metabolism of glucose and 25	  
differential effects on the metabolism of protein. We have shown that, despite similar incorporation, 26	  
treatment of C2C12 myotubes (CM) with EPA but not DHA improves glucose uptake and protein 27	  
accretion. We hypothesized that these differential effects of EPA and DHA may be due to divergent 28	  
shifts in lipidomic profiles leading to altered proteomic profiles. We therefore carried out an 29	  
assessment on the impact of treating CM with EPA and DHA on lipidomic and proteomic profiles. 30	  
FAME analysis revealed that both EPA and DHA led to similar but substantial changes in fatty acid 31	  
profiles with the exception of arachidonic acid, which was decreased only by DHA, and DPA, which 32	  
was increased only by EPA treatment. Global lipidomic analysis showed that EPA and DHA induced 33	  
large alterations in the cellular lipid profiles and in particular, the phospholipid classes. Subsequent 34	  
targeted analysis confirmed that the most differentially regulated species were phosphatidylcholines 35	  
and phosphatidylethanolamines containing long chain fatty acids with 5 (EPA treatment) or 6 (DHA 36	  
treatment) double bonds. As these are typically membrane associated lipid species we hypothesized 37	  
that these treatments differentially altered the membrane-associated proteome. SILAC based 38	  
proteomics of the membrane fraction revealed significant divergence in the effects of EPA and DHA 39	  
on the membrane associated proteome. We conclude that the EPA specific increase in polyunsaturated 40	  
long chain fatty acids in the phospholipid fraction is associated with an altered membrane associated 41	  
proteome and these may be critical events in the metabolic remodelling induced by EPA treatment.       42	  
Keywords: cell signalling, fish oil, fatty acid, insulin, lipidomics, lipids 43	  
  44	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Introduction 45	  
Fatty acids play an important role in skeletal muscle metabolism, not only as substrates for oxidative 46	  
phosphorylation or vital structural components of membranes but also as regulators of enzyme 47	  
activities and signalling molecules (8). Furthermore, dysfunctions in the control of fatty acid 48	  
metabolism can be an important factor in the aetiology of conditions such as insulin resistance and 49	  
muscle atrophy (8). The lipid composition of skeletal muscle undergoes constant fluctuations and is 50	  
reflective of dietary fat intake (6). There is strong evidence to suggest that the enrichment of skeletal 51	  
muscle with omega-3 (n-3) fatty acids may have therapeutic benefits on muscle metabolism and 52	  
function (14). Oral n-3 supplementation above the Reference Dietary Intake is known to result in 53	  
significant incorporation of n-3 fatty acids into the skeletal muscle lipid pool (6, 13, 30).  54	  
Several n-3 supplementation studies in humans have observed beneficial effects ranging from an 55	  
increased sensitivity to anabolic stimuli (43, 44) and muscle function (40, 45).  Eight weeks n-3 56	  
supplementation improved the muscle protein synthetic response (MPS) to a hyperinsulinaemic amino 57	  
acid infusion in both young (44) and elderly individuals (43). Furthermore, when taken alongside a 58	  
resistance based exercise programme (12, 40) or in the absence of any strength training (45) n-3 fatty 59	  
acids enhance strength and or physical function in the elderly. Concurrent with anabolic properties, n-60	  
3 FAs also display anti-catabolic effects. n-3 supplementation prevented muscle mass losses in burned 61	  
guinea pigs (5) and protected against muscle mass loss during anti-neoplastic therapy in cancer 62	  
patients (34). However, when combined in systematic reviews do not always show a beneficial effect 63	  
on muscle mass during cancer treatment (39). Moreover n-3 FAs attenuated soleus atrophy in rodents 64	  
that underwent 10 days of hind limb immobilization (55).  65	  
As well as effects on muscle protein metabolism there is building evidence to suggest that n-3 fatty 66	  
acids may also modulate glucose metabolism. Current meta-analyses detect a neutral or small effect of 67	  
n-3 FAs on measures of insulin sensitivity (4). However, there are several studies across a range of 68	  
models utilizing higher doses of n-3s which support a role for n-3s in improving muscle mitochondrial 69	  
function and glucose metabolism (23, 28, 35, 37, 47, 48).  For instance, replacing 3.4% of the Kcals 70	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with n-3 fatty acids on a high fat diet protects mice against declines in glucose tolerance during a 10-71	  
week high fat diet despite similar increases in body weight compared to high fat alone (28). Whereas 72	  
supplementation studies in humans have not demonstrated a consensus (4),  an interesting lipid 73	  
infusion trial has shown n-3 fatty acids to be bioactive in humans with respect to glucose metabolism 74	  
(46). More specifically, the addition of n-3 fatty acids to a lipid infusion of n-6 fatty acids attenuated 75	  
the decline in insulin stimulated glucose disposal caused by n-6 infusion alone suggesting that the n-3 76	  
fatty acids have a protective effect on glucose metabolism in the presence of an n-6 overload (46).  77	  
Fish oil and n-3 supplements are a heterogeneous mixture of fatty acids of which eicosapentaenoic 78	  
acid (EPA, 20:5) and docosahexaenoic acid (DHA 22:6) are thought to be the most biologically 79	  
active. Due to many studies using a combination of EPA and DHA and varying ratios of each fatty 80	  
acid it is difficult to assert whether EPA or DHA alone is causing the observed effects or if EPA and 81	  
DHA work synergistically or antagonistically for that matter.  The molecular mechanisms of n-3 82	  
action are still poorly understood. Work from Olefsky’s lab suggests that GPR120 acts as a general n-83	  
3 receptor in macrophages and adipocytes that, when activated by n-3 fatty acids leads to increases in 84	  
whole body insulin sensitivity by reducing inflammation (37).  EPA has also been shown to 85	  
antagonise the action of TNFα on C2C12 myotube formation in a manner partially dependent on 86	  
PPARγ (29). Additionally, EPA reduces the activation of Nuclear Factor-κappa Beta (NF-Kb) leading 87	  
to a reduction in Muscle RING finger protein-1 (Murf-1) signalling, an important mediator of muscle 88	  
atrophy in cultured myotubes (22). Furthermore, a follow up study employing both EPA and DHA 89	  
demonstrated that DHA was more efficient in this mechanism than EPA (52). However, EPA has 90	  
been shown to improve metabolic flexibility in response to changing substrate availabilities (21). EPA 91	  
has also previously been shown to improve both basal and insulin stimulated glucose uptake in 92	  
cultured myotubes (1). However, it remains to be seen whether DHA similarly improves glucose 93	  
uptake in skeletal muscle.  Despite the numerous similar intracellular effects and similar structure, 94	  
EPA and DHA may have divergent physiological effects in skeletal muscle.  EPA improves skeletal 95	  
muscle protein metabolism while DHA has a non-significant effect (24). In other striated muscle 96	  
models such as cardiomyocytes, EPA but not DHA increases glucose and fatty acid uptake despite 97	  
	   5	  
similar effects on cell signalling (18).  In plasma both EPA and DHA reduced triacylglycerol (TAG) 98	  
but only DHA modulates HDL (high density lipoprotein) and LDL (low density lipoprotein) particle 99	  
size (53). Collectively these data suggest that in certain contexts, EPA and DHA can have differential 100	  
biological effects. 101	  
The molecular mechanisms underpinning the divergent physiological effects of EPA vs DHA are 102	  
currently under explored. However, differential remodelling of the lipid profile may partially explain 103	  
the divergent physiological response observed between EPA and DHA. Currently studies attempting 104	  
to address how n-3 fatty acids affect the lipidomic profile of skeletal muscle are limited. As expected 105	  
n-3 intake leads to incorporation into the lipid pool of multiple tissues i.e. plasma, muscle, adipose 106	  
tissue and liver with a significant proportion being directed towards phospholipid pools (7, 27, 30, 42-107	  
44).  This incorporation is not limited to the plasma membrane and is also incorporated into 108	  
subcellular organelles such as mitochondria (20). It is hypothesized that a primary driver of the effects 109	  
of EPA and DHA is the displacement of arachidonic acid (AA) from membranes with studies from a 110	  
range of models supporting this (27, 32, 42) while some in vivo human studies observe no change in 111	  
total AA in the skeletal muscle lipid pool (30). However, this does not discount the possibility that 112	  
AA might be displaced from specific lipid fractions. Multiple human studies have assessed the impact 113	  
of n-3 supplementation on skeletal muscle phospholipid pool however the use of a heterogeneous mix 114	  
of n-3 fatty acids precludes the ability to detect the isolated effects of EPA vs DHA on lipid profiles 115	  
(6, 13, 30).  Furthermore, into which skeletal muscle phospholipid fractions EPA and DHA are 116	  
incorporated are poorly understood. In plasma phospholipids EPA and DHA induce a similar lipid 117	  
profile yet EPA increased docosapentanoic acid (DPA 22:5 n-3) and a differential but non-significant 118	  
increase in stearate acid (SA 18:0) (31). In smooth muscle cell phospholipids both EPA and DHA are 119	  
heavily incorporated into the phosphatidylcholine (PC) fraction but EPA is divergently incorporated 120	  
into the phosphatidylinositol (PI) and phosphatidylserine (PS) fraction while DHA is incorporated 121	  
into the phosphatidylethanolamine (PE) fraction (33).  122	  
One of the main cellular fates for fatty acids is incorporation into complex lipid species and so it 123	  
seems logical to hypothesize that the differential action of EPA and DHA may be due to differential 124	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effects on the cellular lipidome. To date no study has characterised the impact of EPA and DHA 125	  
individually on lipidomic profiles in skeletal muscle. In this manuscript we demonstrate that the C2C12 126	  
cell line acts as a model in which EPA and DHA have differential effects on metabolism. We 127	  
followed these experiments by an extensive assessment of lipid changes hypothesizing that the 128	  
divergent effects of EPA and DHA are associated with differential regulation of the skeletal muscle 129	  
lipidome. The lipidomic profiling indicated that multiple membrane associated lipid species were 130	  
differentially altered by EPA and DHA treatments. We therefore hypothesized that the lipidomic 131	  
remodelling would be associated with remodelling of the membrane-associated proteome. SILAC 132	  
based proteomics of the membrane fraction indicated EPA and DHA differentially regulate the 133	  
membrane associated proteome. Therefore, the effects of EPA may be due to membrane associated 134	  
proteomic remodelling secondary to lipidomic remodelling of the membrane-associated lipids. 135	  
  136	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Materials and methods 137	  
Materials 138	  
All plasticware for tissue culture was purchased from fisher scientific (UK). Tissue culture media and 139	  
sera were purchased from Invitrogen. Fatty acids EPA and DHA (>99%, liquid form) were purchased 140	  
from Sigma Aldrich (Dorset, UK). H32-DG was purchased from Hartman Analytic. All solvents were 141	  
LC-MS grade (Fisher Scientific, Loughborough, UK). 142	  
Cell culture 143	  
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 20% fetal 144	  
bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 5% C02. Myoblasts were 145	  
maintained at ~60% confluence. Differentiation was induced once confluence reached 80-90% by 146	  
changing the media to differentiation media (DMEM supplemented with 2% horse serum and 1% 147	  
Penicillin/Streptomycin) for 72 hours. Following 72 hours differentiation cells were treated with 50 148	  
µM EPA or 50 µM DHA pre-bound to 2% fatty acid free BSA for 72 hours before collection. As a 149	  
control cells were treated with 2% fatty acid free (FAF) BSA for 72 hours before collection. Fatty 150	  
acids were conjugated to 2% fatty acid free BSA in DM by constant agitation for 1 hour at 37°C. 151	  
Following treatment cell pellets were collected following 3 washes in 2% FAF BSA in PBS and 152	  
centrifuged at 800 rpm for 4 minutes, excess liquid was removed and pellets were frozen in liquid 153	  
nitrogen and stored at -80°C until further analysis. 154	  
FAME analysis 155	  
Total lipids were extracted by homogenising in 20 volumes of chloroform/methanol (2:1 v/v). Total 156	  
lipids were prepared according to the method of Folch et al. (17) and non-lipid impurities were 157	  
removed by washing with 0.88% (w/v) KCl. The weight of lipids was determined gravimetrically 158	  
after evaporation of solvent and overnight desiccation under vacuum. Fatty acid methyl esters 159	  
(FAME) were prepared by acid-catalysed transesterification of total lipids according to the method of 160	  
Christie et al. (35). Extraction and purification of FAME was performed as described by Ghioni et al. 161	  
(36). FAME were separated by gas-liquid chromatography using a ThermoFisher Trace GC 2000 162	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(ThermoFisher, Hemel Hempstead, UK) equipped with a fused silica capillary column (ZBWax, 60m 163	  
x 0.25 µm x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with hydrogen as carrier gas and using 164	  
on-column injection. The temperature gradient was form 50 to 150oC at 40oC/min and then to 195oC 165	  
at 1.5oC/min and finally to 220oC at 2oC/min. Individual methyl esters were identified by reference to 166	  
published data (Ackman, 1980). Data were collected and processed using the Chromcard for 167	  
Windows (version 2.00) computer package (Thermoquest Italia S.p.A., Milan, Italy). All experiments 168	  
were carried in duplicate from 4 independent experiments. Data were represented as fold change from 169	  
the respective BSA control condition, logged to log2 and significance was determined by t-test and 170	  
corrected for false discovery rate.   171	  
Global lipidomic analysis of C2C12 myotubes 172	  
Lipid extraction was performed according to the method described above. The lipids were analysed by 173	  
liquid chromatography-mass spectrometry (LC-MS) using a Thermo Exactive Orbitrap mass 174	  
spectrometer (Thermo Scientific, Hemel Hempstead, UK), equipped with a heated electrospray 175	  
ionization probe and coupled to a Thermo Accela 1250 UHPLC system. All samples were analysed in 176	  
both positive and negative ion mode over the mass to charge (m/z) range 200-2000. The lipids were 177	  
separated on to a Thermo Hypersil Gold C18 column (1.9 µm, 2.1mm x 100 mm,). Mobile phase A 178	  
consisted of water containing 10 mM ammonium formate and 0.1% (v/v) formic acid. Mobile phase B 179	  
consisted of 90:10 isopropanol/acetonitrile containing 10 mM ammonium formate and 0.1% (v/v) 180	  
formic acid. The initial conditions for analysis were 65%A/35%B. The percentage of mobile phase B 181	  
was increased to 100% over 10 min and held for 7 minutes before re-equilibration with the starting 182	  
conditions for 4 minutes. The raw LC-MS data were processed with Progenesis QI v2.0 software 183	  
(Non-linear Dynamics, Newcastle, UK) and searched against LIPID MAPS (www.lipidmaps.org) and 184	  
the Human Metabolome Database (http://www.hmdb.ca/) for identification. All experiments were 185	  
carried out in duplicate from three independent experiments. 186	  
 187	  
Phospholipid profiling of C2C12 myotubes  188	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In order to assess the incorporation of EPA and DHA into cellular phospholipids the lipid extracts 189	  
from C2C12 myotubes were analysed by electrospray ionisation-tandem mass spectrometry (ESI-190	  
MS/MS).  All analyses were performed using a Thermo TSQ Quantum Ultra triple quadrupole mass 191	  
spectrometer equipped with a heated electrospray ionization probe. Samples were directly infused into 192	  
the ion source at a flow rate of 5 µL/min. Phosphatidylcholine, lysophosphatidylcholine and 193	  
sphingomyelin species were identified by precursor scanning for mass to charge ratio (m/z) 184 in 194	  
positive ion mode.  Phosphatidylethanolamine and lysophosphatidylethanolamine species were 195	  
identified by neutral loss scanning for m/z 141 in positive ion mode. Phosphatidylserine species were 196	  
identified by neutral loss scanning for m/z 87 in negative ion mode. Phosphatidylinositol species were 197	  
identified by precursor scanning for m/z 241 in negative ion mode. The data were expressed as a 198	  
percentage composition of the relevant phospholipid fraction. 199	  
 200	  
Glucose uptake 201	  
C2C12 myotubes, were exposed to 50µM EPA or 50µM DHA pre-bound to 2% fatty acid free BSA 202	  
or 2% fatty acid free BSA as a control for 48 h before a 2 h serum-starve. Following the 2 h serum 203	  
starve cells were exposed to insulin (100 nmol/l) or vehicle control for 30 mins. Myotubes were 204	  
incubated (12 min) with 10 µmol/l 2-deoxy-D-[3 H]glucose (2DG; 24.4 kBq/ml; Hartman Analytic) at 205	  
20°C. Non-specific uptake was determined using 10 µmol/l cytochalasin B (Sigma–Aldrich). After 206	  
lysis, cell-associated radioactivity was measured (Beckman, High Wycombe, UK; LS 6000IC 207	  
scintillation counter), and protein was quantified using the Bradford reagent. Data represented are the 208	  
average of 6 independent experiments carried out in duplicate. 209	  
Mitochondrial function 210	  
C2C12 myotubes, were exposed to 50µM EPA or 50µM DHA pre-bound to 2% fatty acid free BSA 211	  
or 2% fatty acid free BSA as a control for 48 h. Following 48 h in the respective treatments cells were 212	  
degassed and exposed to a mito-stress test in the Seahorse cellular respiration analyser as previously 213	  
described (16). 214	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Muscle protein synthesis and muscle protein breakdown 215	  
Protein	  degradation	  was	  assessed	  by	  the	  quantification	  of	  the	  released	  L-­‐[2,4,3H]	  phenylalanine	  into	  216	  
the	   culture	   media.	   Following	   4	   days	   of	   differentiation	   myotubes	   were	   incubated	   with	   medium	  217	  
containing	  2.5	  µCi	  L-­‐[2,4,3H]	  phenylalanine/ml	  and	  the	  label	  was	  maintained	  for	  24	  hours	  in	  order	  to	  218	  
label	  long	  lived	  proteins.	  Following	  the	  pulse	  the	  cells	  were	  washed	  2x	  in	  PBS	  and	  incubated	  in	  cold	  219	  
chase	  media	   (DMEM	   +	   2mM	   L-­‐phenylalanine)	   for	   3	   hours	   to	   allow	   for	   degradation	   of	   short	   lived	  220	  
proteins.	  Myotubes	  were	  then	  treated	  with	  either	  50	  µM	  EPA/DHA	  bound	  to	  2%	  FAF-­‐BSA	  or	  2%	  FAF-­‐221	  
BSA	  alone	   for	  24	  hrs.	   Following	   treatment	  an	  aliquot	  of	   the	  media	  was	   removed	  and	   radioactivity	  222	  
released	   was	   assessed	   by	   scintillation	   counting.	   The	   remaining	   myotubes	   were	   then	   thoroughly	  223	  
washed	  with	  ice	  cold	  saline	  (0.9%)	  and	  lysed	  with	  50mM	  NaOH	  +	  1%	  SDS	  for	  a	  minimum	  of	  30	  mins	  224	  
at	   room	   temperature.	   Residual	   radioactivity	   in	   cell	   lysates	   was	   then	   assessed	   by	   scintillation	  225	  
counting.	  Total	  radioactivity	  was	  calculated	  as	  the	  sum	  of	  the	  L-­‐[2,4,3H]	  phenylalanine	  released	  into	  226	  
the	  media	  and	  the	  residual	  cell	  retained	  L-­‐[2,4,3H]	  phenylalanine.	  Protein	  breakdown	  is	  presented	  as	  227	  
the	  fraction	  of	  the	  total	  incorporated	  L-­‐[2,4,3H]	  phenylalanine	  released	  into	  the	  media.	  228	  
	  229	  
Basal	  protein	   synthesis	  was	  assessed	  by	   the	   incorporation	  of	   L-­‐[2,4,3H]	  phenyalalnine	   into	  peptide	  230	  
chains.	  Following	  differentiation,	  myotubes	  were	  treated	  with	  either	  50	  µM	  EPA/DHA	  bound	  to	  2%	  231	  
FAF-­‐BSA	  or	  2%	  FAF-­‐BSA	  alone	  for	  24	  hrs.	  At	  the	  end	  of	  the	  treatment	  period	  the	  media	  was	  removed	  232	  
and	   DMEM	   containing	   1µCi	   L-­‐[2,43H]	   phenylalanine	   (0.5	   µCi/ml)	   was	   added	   for	   180	   mins.	   The	  233	  
reaction	  was	  stopped	  by	  2x	  washes	  in	  ice	  cold	  saline	  (0.9%)	  before	  3x	  washes	  with	  Tricholoroacetic	  234	  
acid	   (TCA)	   (10%)	   to	   remove	  any	  unincorporated	   tracer.	  Residual	  TCA	  was	   then	  removed	  by	   rinsing	  235	  
cells	  with	  methanol	  and	  plates	  left	  to	  dry.	  	  Myotubes	  were	  then	  lysed	  in	  50mM	  NaOH	  +	  1%	  SDS	  for	  a	  236	  
minimum	   of	   30	   minutes.	   An	   aliquot	   was	   collected	   for	   liquid	   scintillation	   counting	   to	   assess	   3H	  237	  
incorporation	  into	  proteins	  and	  the	  remaining	  lysate	  was	  used	  to	  determine	  protein	  content	  by	  the	  238	  
DC	  protein	  assay.	  Protein	  synthesis	  is	  presented	  as	  counts	  per	  minute/µg	  of	  protein. 239	  
 240	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Protein content 241	  
Protein content following 72 h treatment with 50µM EPA or 50µM DHA pre-bound to 2% fatty acid 242	  
free BSA or 2% fatty acid free BSA as a control was determined by multiplying the concentration of 243	  
the supernatant [as determined using the bicinchoninic acid protein assay according to the 244	  
manufacturer’s instructions (Sigma Aldrich, UK)] by the total volume of supernatant collected from a 245	  
6 well plate. Data are representative of 5 independent experiments carried out in triplicate. 246	  
 247	  
Cell processing  248	  
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 mmol/l Tris·HCl 249	  
pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 1 mmol/l EDTA, 1% (vol/vol) 250	  
Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 mmol/l sucrose, and 0.1% (vol/vol) 2-251	  
mercaptoethanol and Complete protease inhibitor cocktail (Roche)] followed by snap freezing on 252	  
liquid nitrogen. For preparation for western blotting samples were thawed and debris was removed by 253	  
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and protein 254	  
concentration was determined using the bicinchoninic acid protein assay according to the 255	  
manufacturer’s instructions (Sigma Aldrich, UK).  256	  
 257	  
Western blotting 258	  
For WB, 100µg of supernatant was made up in Lamelli sample buffer, and 15 µg of total protein was 259	  
loaded per well and run at 150 V for 1 h 15 min. Proteins were then transferred onto Whatman 260	  
Immunobilon Nitrocellulose membranes (Fisher Scientific, Loughborough, UK) at 30 V overnight on 261	  
ice. Membranes were blocked in 3% BSA-Tris-buffered saline (containing vol/vol 0.1% Tween 20) 262	  
for 1 h at room temperature, followed by incubation in primary antibodies [PKBthr308 (#2965) or 263	  
total PKB (#4691) GLUT 1(Santa cruz, sc-7903), GLUT4 (#2213S), Hexokinase 1 (#2204S), 264	  
Hexokinase 2 (#2867S), Mito profile (abcam, #ab110413) (New England Biolabs unless stated)] at 265	  
4°C overnight. Membranes underwent three 5 min washes in TBST followed by incubation in the 266	  
appropriate secondary antibodies [secondary horseradish peroxidase conjugated antibody was 267	  
purchased from ABCAM (#6721)] for 1 h at room temperature. Membranes were again washed three 268	  
	   12	  
times for 5 min followed by incubation in enhanced chemiluninescence reagent (BioRad, Herts, UK). 269	  
A BioRad ChemiDoc (Herts, UK) was used to visualize and quantify protein expression. Phospho-270	  
PKB was normalized to the corresponding total protein. Data are representative of 3 independent 271	  
experiments carried out in duplicate. 272	  
Membrane proteome  273	  
Proteins associated with membranes were assessed using the SILAC proteomic method (38). C2C12 274	  
myoblasts were grown in Dulbeccos’ modified eagles medium (DMEM) supplemented with 20% 275	  
dialysed (10 kKDa) foetal bovine serum plus labelled amino acids lysine and arginine in a humidified 276	  
atmosphere of 37°C and 5% CO2. Cells intended to act as the control group were grown in with 277	  
unlabelled lysine and arginine (light), the EPA treatment group were grown in R6K4 media (l-278	  
arginine-13C6 hydrochloride, l-lysine-4,4,5,5-d4 hydrochloride[medium]) while the DHA treatment 279	  
group were grown with R10K8 containing media (l-arginine-13C6, 15N4 hydrochloride, l-lysine-280	  
13C6,15N2 hydrochloride [Heavy]). The use of combined labelled arginine and lysine ensures that 281	  
nearly all peptides will contain a label after tryptic digestion. Cells were allowed to grow for at least 6 282	  
population doublings to ensure full incorporation of labelled amino acids. We observed that use of 283	  
dialysed sera and labelled media did not affect doubling time, cell morphology or differentiation 284	  
capacity. Upon reaching 90-100% confluence the media was replaced with DMEM containing 2% 285	  
dialysed donor horse serum (10 kDa) to induce differentiation. After 3-4 days of differentiation, 286	  
myotubes were treated with either control, 50µM EPA or 50 µM DHA for 72 hours. For membrane 287	  
proteome analysis, membranes were isolated using the Thermo scientific Mem per plus protein 288	  
membrane extraction kit. The membrane proteome was assessed by LC-MS/MS. 289	  
Mass spectrometry 290	  
The resulting peptides were fractionated using an Ultimate 3000 nanoHPLC system in line with an 291	  
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  In brief, peptides in 1% (vol/vol) 292	  
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 293	  
washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 250 294	  
mm × 75 µm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 295	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min organic gradient, using 7  gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 296	  
15-32%B over 58min., 32-40%B over 5min., 40-90%B over 1min., held at 90%B for 6min and then 297	  
reduced to 1%B over 1min.) with a flow rate of 300 nl min−1.  Solvent A was 0.1% formic acid and 298	  
Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-299	  
electrospray ionization at 2.0 kV using a stainless steel emitter with an internal diameter of 30 µm 300	  
(Thermo Scientific) and a capillary temperature of 275°C.  301	  
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 302	  
2.1 software (Thermo Scientific) and operated in data-dependent acquisition mode.  FTMS1 spectra 303	  
were collected at a resolution of 120 000 over a scan range (m/z) of 350-1550, with an automatic gain 304	  
control (AGC) target of 300 000 and a max injection time of 100ms. Precursors were filtered using an 305	  
Intensity Range of 1E4 to 1E20 and according to charge state (to include charge states 2-6) and with 306	  
monoisotopic precursor selection. Previously interrogated precursors were excluded using a dynamic 307	  
window (40s +/-10ppm). The MS2 precursors were isolated with a quadrupole mass filter set to a 308	  
width of 1.4m/z. ITMS2 spectra were collected with an AGC target of 20 000, max injection time of 309	  
40ms and CID collision energy of 35%. 310	  
Quantification and bioinformatics analysis 311	  
The raw mass spectrometric data files obtained for each experiment were collated into a single 312	  
quantitated data set using MaxQuant (version 1.2.2.5) (10) and the Andromeda search engine software 313	  
(11). Enzyme specificity was set to that of trypsin, allowing for cleavage N-terminal to proline 314	  
residues and between aspartic acid and proline residues. Other parameters used were: (i) variable 315	  
modifications, methionine oxidation, protein N-acetylation, gln à pyro-glu, Phospho(STY); (ii) fixed 316	  
modifications, cysteine carbamidomethylation; (iii) database: target-decoy human MaxQuant 317	  
(ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS tolerance: FTMS- 10ppm , 318	  
ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) maximum missed cleavages, 2; (viii) maximum 319	  
of labeled amino acids, 3; and (ix) false discovery rate, 1%. Peptide ratios were calculated for each 320	  
arginine- and/or lysine-containing peptide as the peak area of labeled arginine/lysine divided by the 321	  
peak area of nonlabeled arginine/lysine for each single-scan mass spectrum. Peptide ratios for all 322	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arginine- and lysine-containing peptides sequenced for each protein were averaged. Data is 323	  
normalised using 1/median ratio value for each identified protein group per labelled sample. 324	  
Statistics 325	  
Statistical analyses were carried out in Graphpad Prism with ANOVA followed by Tukey’s HSD test. 326	  
For FAME analyses data were assessed in R statistical packages and tested by t-test and corrected by 327	  
false discovery rate. Statistical significance was determined with a p<0.05. The global lipidomic data 328	  
sets were subjected to principal component analysis (PCA) and orthogonal projection latent structure-329	  
discriminant analysis (OPLS-DA) with Pareto scaling using SIMCA-P v13.0 software (Umetrics, 330	  
Umea, Sweden). The OPLS-DA models were validated by using the internal cross-validation 331	  
function. Membrane protein abundance was considered altered if fold change was lower than 0.75 or 332	  
greater than 1.25. Enrichment of biological processes was determined using gene ontology, using the 333	  
whole genome of Mus musculus as a background reference list. 334	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Results 336	  
EPA and DHA substantially increase the abundance of omega-3 species but have differential 337	  
effects on individual omega-3 fatty acids.  338	  
After exposure to 50uM EPA or DHA for 72 hrs C2C12 myotubes were collected for FAME analysis 339	  
to determine lipid profiles. EPA and DHA significantly increased total omega-3 fatty acid content 340	  
from baseline values (EPA; 951 ± 81% p=0.0014, DHA; 750 ± 56% p=0.0009) with no significant 341	  
difference detected between EPA and DHA treatment (p=0.115) (Figure 1). The changes in omega-3 342	  
abundance are a result of differential shifts in specific omega-3 fatty acids caused by EPA or DHA 343	  
treatment. The increase in omega-3 content by DHA is a result of accumulation of mainly DHA [22:6 344	  
n-3, 3050% ± 310% (Figure 5)]. While, incubation of myotubes with EPA results in the accumulation 345	  
of EPA [(20:5 n-3), 1630% ± 23.38] and DPA [(22:5 n-3), 1318% ± 199.8%] (Figure 5). These data 346	  
suggest that EPA is elongated to DPA whilst DHA remains largely unmodified. 347	  
EPA and DHA have differential effects on skeletal muscle glucose uptake.  348	  
Insulin stimulated 2-deoxy-glucose (2DG) uptake was determined after 48 h in either EPA or DHA. 349	  
EPA treatment significantly increased both basal and insulin stimulated 2DG uptake indicating that 350	  
EPA treatment increases the capacity for glucose uptake (Figure 2A). DHA did not have any 351	  
significant effects on 2DG uptake (Figure 2A). The observed changes in 2DG uptake did not appear 352	  
to be related to any change in insulin stimulated PKB phosphorylation as phospho-blot analysis 353	  
revealed that insulin stimulated PKB phosphorylation was the same between treatments and controls 354	  
(Figure 2B). In addition EPA/DHA treatment did not appear to affect GLUT1 or GLUT4 expression 355	  
(Figure 1C), nor did they appear to affect the expression of Hexokinase 1 or Hexokinase 2 (Figure 356	  
1D). 357	  
EPA and DHA treatment does not alter mitochondrial respiration. 358	  
As no changes in glucose transporters were detected we next assessed whether changes in 359	  
mitochondrial oxygen consumption may explain the increase in glucose uptake following EPA 360	  
treatment. C2C12 myotubes were treated with 50uM EPA or DHA for 24 hours. Following treatment 361	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multiple inhibitors/uncouplers (Oligomycin, FCCP, rotenone/anitmycin A) were used to probe various 362	  
parameters of mitochondrial function using the seahorse XF mito stress test. A two way ANOVA 363	  
found a significant interaction between oxygen consumption and inhibitor compound, indicating the 364	  
successful manipulation of mitochondrial function (Figure 3A). However, fatty acid treatment did not 365	  
lead to changes in cellular oxygen consumption on any parameter measured (Figure 3A). Consistent 366	  
with the lack of changes in mitochondrial function, there were no alterations in the abundance of ATP 367	  
synthase and UCQR2 (Complex V and Complex III respectively) (Figure 3B/C). 368	  
EPA enhances protein accretion through a reduction in protein breakdown while DHA has a 369	  
neutral effect 370	  
After a 72 hour incubation with EPA or DHA, myotubes were collected in order to determine total 371	  
protein content. When myotubes were incubated with EPA total protein content was enhanced while 372	  
incubation with DHA had a neutral effect (Figure 4C). Protein balance is determined by the balance 373	  
between synthesis and breakdown of proteins. Thus, the observed protein accretion may be reflected 374	  
in changes in either protein synthesis or breakdown. In order to understand the mechanisms 375	  
underlying the changes in protein content we directly assessed protein synthesis and breakdown and 376	  
related signalling processes. Neither fatty acid had any effect on basal protein synthesis after a 24-377	  
hour incubation (Figure 4A). Anabolic signalling assessed by the phosphorylation status of mTOR, 378	  
P70S6K1 and 4E-BP1 were not different between groups, corresponding with lack of changes in 379	  
protein synthesis (Figure 4E/F). EPA reduced protein breakdown compared to both the vehicle and 380	  
DHA treatments (Figure 4B). No changes were detected in the level of ubiquitin tagged proteins 381	  
(Figure 4D/F). 382	  
EPA treatment differentially regulates DPA levels whilst DHA treatment differentially regulates 383	  
arachidonic acid levels. As previously mentioned, incubation of C2C12 with 50 µM EPA or 50 µM 384	  
DHA led to substantial cellular incorporation of total omega-3 fatty acids (Figure 1A). This was 385	  
associated with the above mentioned physiological changes. In order to determine the potential 386	  
mechanisms by which these effects occur we determined via FAME analysis the fatty acid changes 387	  
responsible for the increase in total n-3 levels in the cells treated with EPA/DHA. In order to clearly 388	  
	   17	  
distinguish differential fatty acid shifts we presented the complete fatty acid profiles as fold change 389	  
[(log2) Figure 5]. The most clearly differentiated fatty acid is DPA (22:5 n3) which demonstrates a 390	  
significant 1318 ± 200% increase with EPA treatment whilst DHA treatment induces a 17.83 ± 391	  
17.37% decrease in DPA content. Additionally there is a trend (p=0.06) for EPA treatment to increase 392	  
the DHA content of the cells (37.11 ± 12.62%) suggesting that only a small proportion of the EPA is 393	  
converted to DHA.  Surprisingly arachidonic acid (20:4 n6) was only significantly decreased by DHA 394	  
treatment (-22.35 ± 3.174%) and remained unaffected by EPA treatment. Intriguingly we also 395	  
observed that both EPA and DHA increased the content of the saturated fatty acid palmitate (PA 16:0) 396	  
(Figure 5). In order to build a more complete picture of the impact of EPA and DHA on the lipidome 397	  
we proceeded with a global lipidomics assessment. 398	  
Global lipidomics reveals that EPA and DHA treatments induce substantial divergence in the 399	  
lipidome. Lipid extracts of cells treated with BSA (control), EPA or DHA were analysed by LC-MS 400	  
in positive and negative ion modes, processed and subjected to multivariate data analysis. PCA 401	  
highlights any natural clustering or separation within a data set and thereby enables similarities or 402	  
differences between study groups to be explored. The PCA scores plots of both the positive and 403	  
negative ion data sets revealed that EPA and DHA supplementation caused a substantial divergence in 404	  
the lipidome, effectively segregating control and treated cells (Fig. 6A and 6B). Having established 405	  
the existence of clustering behaviour between the sample cohorts more powerful multivariate methods 406	  
were used to characterise the specific lipid changes responsible for the observed shift in the lipidome 407	  
of the EPA and DHA treated myotubes. The OPLS-DA scores plots and associated ‘S’ plots of the 408	  
positive ion data are shown in Fig. 7A and 7B. The results indicated that many of the key 409	  
discriminating lipids associated with EPA and DHA treatment were phospholipids and in particular 410	  
molecular species of PC and PE.. In EPA treated cells elevations in PC and PE species containing 411	  
both 20:5 and 22:5 fatty acids (in agreement with FAME analysis) were observed, whereas there were 412	  
relative increases in the abundance of phospholipid species with a 22:6 fatty acid in DHA treated 413	  
cells. The analysis also revealed that both EPA and DHA treatments also resulted in an elevation of 414	  
PC 32:0, a saturated species. DHA was also found to be incorporated into a number of triglyceride 415	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species (see supplemental). In order to fully understand the impact of EPA and DHA treatment we 416	  
followed up these experiments through the targeted analysis of the myotube phospholipids.  417	  
Targeted phospholipid analysis reveals that EPA and DHA increase the fraction of lipid species 418	  
containing long chains and 5 or more double bonds at the expense of shorter chain, less 419	  
saturated species. ESI-MS/MS was utilised to characterise the profiles of myocyte phospholipid 420	  
classes. Representative mass spectra of PC and PE are shown in Figure 8A and 8B. The general 421	  
trends (Figure 9) in both EPA and DHA were similar with the displacement of shorter chain in 422	  
apparent preference for longer chain highly unsaturated fatty acids. However, the magnitude of 423	  
change for these displacements was often higher with DHA. There was no evidence of alterations in 424	  
the profile of sphingomyelin species in response to fatty acid treatments. ESI-MS/MS analysis of PS 425	  
and PI was also performed however the low signal intensities of these lipids did not permit a robust 426	  
quantification. Interestingly EPA and DHA supplementation led to a higher abundance of 427	  
phospholipid species containing saturated fatty acids. For instance DHA induced an increase in PC 428	  
(32:0) and lysophosphatidylethanolamine (LPE) (16:0), whilst EPA induced an increase in PC (32:0,) 429	  
LPC (16:0), (18:0) and LPE (18:0). It is therefore evident that in spite of significant increases in 430	  
saturated fatty acids in these EPA and DHA treatment still improve or maintain glucose uptake 431	  
respectively.   432	  
Altered composition of phospholipids is associated with altered membrane associated proteomic 433	  
profiles. 434	  
As the lipidomic remodelling indicated substantial changes induced by n-3 treatment in the membrane 435	  
associated lipid species we carried out SILAC based proteomics profiling of the membrane fraction to 436	  
assess if the lipid remodelling altered the proteins in the membrane fraction. Over 3000 proteins 437	  
associated with the membrane compartment were identified in the SILAC screen. These results were 438	  
filtered down to 625 proteins (see supplemental) with a coefficient of variance ≤ 5% to describe 439	  
consistent changes in membrane abundance.  Proteins were considered enriched or reduced in the 440	  
membrane with a fold change cut off of 0.25. Proteins similarly affected by EPA and DHA were 441	  
removed from analysis. Proteins with altered abundance were then subject to gene ontology analysis 442	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for biological processes (see supplemental). Membrane proteins altered by EPA were associated with 443	  
protein folding (p = 4.76E-03). Additionally, these proteins were subjected to String analysis which 444	  
revealed that these proteins were highly likely to interact with eachother (Figure 10B). EPA also 445	  
increased Calumenin in the membrane fraction (1.34 fold).  Interestingly, Calumenin plays a role in 446	  
calcium sensitive protein folding (49). DHA altered proteins associated with a number of processes, 447	  
primarily related to oxidative metabolism and ribosomal formation (see table 1). Further examination 448	  
of ribosomal proteins revealed that DHA induced the significant reduction in ribosomal proteins 449	  
associated with both small and large subunits at the membrane (Figure 10C). Conversely, EPA 450	  
induced a small increase in ribosomal proteins (Figure 10C). 451	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Discussion 453	  
This study is the first to carry out a comprehensive analysis of the lipidomic profiles of a skeletal 454	  
muscle cell line in response to two differentially bioactive n-3 fatty acids. Furthermore, it is the first 455	  
study, to our knowledge, to combine this with a profile of the membrane associated proteome. We 456	  
clearly demonstrate the differential metabolic activities of EPA vs DHA in the C2C12 skeletal muscle 457	  
cell line and provide data demonstrating the differential impact that EPA and DHA have on the 458	  
skeletal muscle lipidome. Our data suggests that the bioactivity of EPA may be due to its preferential 459	  
incorporation (and possibly elongation to DPA) into the phospholipid fraction where it substantially 460	  
alters the long chain polyunsaturated fatty acid composition of major phospholipid classes. Likely 461	  
secondary to the alterations in membrane associated phospholipids we see an altered membrane 462	  
associated proteome. These changes in the membrane lipid-protein composition may be a key driver 463	  
for the metabolic effects of n3 fatty acids. 464	  
Similar to previous cell culture based studies (1, 21), we show that EPA has a positive effect on 465	  
glucose uptake. Both basal and insulin stimulated muscle glucose uptake were improved by EPA but 466	  
not DHA. The increase in glucose uptake appears to be independent of changes in PKB signalling as 467	  
measured by phosphorylation status which suggests that enhanced proximal insulin and possibly PKB 468	  
signalling are not part of the mechanism of action. Furthermore, there was no significant change to the 469	  
expression of the glucose transporters GLUT1/4, hexokinase1/2 or the mitochondrial enzymes 470	  
UQCRC2 and ATP-synthase. Nor was there any significant change in mitochondrial function as 471	  
assessed by the mitochondrial stress test. These data are difficult to consolidate, however, we 472	  
hypothesize that the mechanism of action of EPA on glucose uptake may be dependent less upon 473	  
changes in protein expression and more dependent upon protein localisation perhaps improving the 474	  
functional coupling of glucose metabolism enzymes.     475	  
In addition to the EPA induced improvements in glucose uptake we also noted a significant 476	  
improvement in protein accretion with EPA treatment, while DHA showed no significant effect. To 477	  
determine the mechanism by which cells treated with EPA accumulate more protein we assessed 478	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muscle protein synthesis and muscle protein breakdown. While Kamolrat et al (24) observed 479	  
enhanced leucine stimulated MPS following EPA treatment, we detected no significant changes in  480	  
basal muscle protein synthesis or the phosphorylation of anabolic signalling markers. Instead, we 481	  
determined that the effect of EPA on protein accretion was likely driven by an ~10% reduction in 482	  
muscle protein breakdown. Analysis of global ubiquitination via western blotting indicates that the 483	  
reduction in muscle protein breakdown may not be driven by a change in the activity of the ubiquitin 484	  
system. Rather, it may be driven by reduced lysosomal degradation (9). In saying that we must 485	  
concede however, that a 10% reduction in ubiquitin driven protein breakdown would be challenging 486	  
to detect via western blotting.  487	  
In an effort to determine the molecular mechanism of action of EPA on skeletal muscle glucose 488	  
uptake and protein accretion we tested the hypothesis that EPA and DHA treatments would induce 489	  
significant lipid remodelling leading to remodelling of the cellular proteome. We found that while the 490	  
total n-3 content was similar between treatments, EPA resulted in a larger variation in lipid species 491	  
accumulating mainly as EPA and DPA and to a lesser extent DHA while DHA treatment mainly 492	  
resulted in DHA accumulation with a decrease in DPA and a limited retro-conversion to EPA. The 493	  
main differentially regulated fatty acids were DPA, increased in EPA and decreased in DHA, while 494	  
only DHA decreased AA. Interestingly DPA accumulated to a similar extent as EPA [1630% (EPA) 495	  
vs 1318% (DPA)], findings consistent with previous literature in other tissues (2, 26). Given that DPA 496	  
increased to a similar extent to EPA we are unable to determine whether it is EPA or DPA that is the 497	  
main driver behind the metabolic effects observed. These data suggest that upon intake into the cell 498	  
EPA is elongated to DPA and to a lesser extent DHA. The elongation of EPA to DPA but not DHA 499	  
may be explained by the differential affinities of the desaturases and elongases involved in fatty acid 500	  
metabolism. In the n-3 pathway elovl2 catalyzes the conversion of EPA → DPA → 24:5 n-3, the 501	  
precursor to DHA. However, increasing EPA concentrations is known to lower the saturation point in 502	  
the conversion of DPA → 24:5 n-3 which may play a role the accumulation of DPA without being 503	  
further metabolised to DHA (19). Our data indicate that one of the primary fates of EPA and DHA 504	  
was incorporation into the phospholipid fraction. In the global lipidomics screen we found EPA or 505	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DPA containing lipid species associated with the phospholipid pool whilst DHA containing species 506	  
were often associated with the TAG pool whilst EPA containing species were rarely associated with 507	  
the TAG pool (see supplemental spread sheet). Fatty acids in the TAG pool are stored in discrete lipid 508	  
droplets and therefore may be less metabolically active than the phospholipids associated with the 509	  
membranes. This differential incorporation into the various lipid pools may partially explain the 510	  
beneficial metabolic effects of EPA.  511	  
The potential relevance of DPA as a mediator of many of the physiological effects of n-3 512	  
supplementation is beginning to be further understood. DPA more potently inhibits platelet 513	  
aggregation than EPA or DHA (3) as well as more potently stimulating endothelial cell migration than 514	  
EPA or DHA (25). In macrophages EPA is a known inhibitor of the cyclooxygenase pathway and 515	  
elongation to DPA is an important factor in this inhibition (36). We would suggest that the elongation 516	  
of EPA to DPA seen in our study may also have important physiological roles in the increase in 517	  
skeletal muscle glucose uptake by EPA. As with the global lipidomic analysis we observed the 518	  
incorporation of long chain PUFAs into phospholipid species mainly at the expense of specific SFAs 519	  
and MUFAs, however some specific SFAs were increased by both EPA and DHA. We identified 520	  
multiple differentially regulated phospholipid species across PE, PC, LPE and LPC classes. In the 521	  
EPA treated group a number of species were enriched by long chain PUFAs with 5 or more double 522	  
bonds in addition to a number of EPA or DPA containing phospholipids in the PC and PE, fractions In 523	  
comparison, the DHA treated group increased the long chain PUFA containing phospholipids but did 524	  
not increase or increase as much as EPA the content of species containing 22:5 or 40:5. Interestingly, 525	  
with DHA treatment there was a trend for an increase in the palmitate containing lyso-PE content 526	  
above that of control and EPA. Additionally, while it appears that many phospholipids containing 527	  
saturated fatty acids are displaced in favour of polyunsaturated containing phospholipids we observe a 528	  
rise in PC (32:0) with both EPA and DHA, which may reflect the rise in palmitate observed with 529	  
FAME analysis. Incorporation of PUFAs into phospholipids is known to increase membrane fluidity 530	  
and we speculate that this increase may be a compensatory mechanism to maintain a base level of 531	  
membrane rigidity.  532	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An attractive mechanism for the differential effects of EPA and DHA may lie in the reduced 533	  
production of different inflammatory eicosanoids. However, only DHA reduced the total amount of 534	  
AA. Additionally, the displacement of phospholipids alongside a lack of inflammatory stimulus 535	  
suggests it is unlikely that this would mediate the metabolic differences seen in this model.  The G 536	  
protein coupled receptor GPR120 has previously been identified as a general n-3 sensor in a number 537	  
of tissues except skeletal muscle that elicits potent anti-inflammatory and consequently insulin 538	  
sensitizing effects (37). To our knowledge no such receptor exists in skeletal muscle that can 539	  
discriminate between EPA and DHA deeming it unlikely that the observed differential effects are 540	  
mediated by EPA or DHA through specific receptor activated signalling.   541	  
Phospholipid species are not merely inert structural components of cellular membranes and their 542	  
various roles in intracellular processes are beginning to be further understood. PS and PE are related 543	  
phospholipid species found predominantly in the inner membrane and contribute to the membrane 544	  
targeting and activation and modification of protein kinases [as reviewed (51)]. It has also previously 545	  
been seen that the lyso-PC, a hyrdrolyzed form of phospholipid, stimulated adipocyte glucose uptake 546	  
in a manner dependent upon chain length and saturation of the acyl group (54). We observed an 547	  
incorporation of long chain PUFAs (possibly EPA and DPA) into the PC, PS, PE and certain lyso-PL 548	  
species and therefore cannot discount that the change in acyl chain length and unsaturation level alters 549	  
the function of these PL species and leads to an increase in glucose uptake through a currently 550	  
unknown mechanism. Because, the lipid composition of the membrane can alter the targeting of 551	  
various proteins to the membrane (50, 51) we speculated that part of the mechanism of action of EPA 552	  
might be via a change in the composition of the membrane associated proteome. To test this theory 553	  
we carried out a 3 way SILAC experiment on the membrane fractions of cells treated with vehicle, 554	  
EPA or DHA.   555	  
Our SILAC experiment illustrated the proof of concept that the incorporation of EPA and DHA into 556	  
phospholipid species was associated with the alteration of proteins interacting with the membrane 557	  
compartment. There are a number of mechanisms by which proteins can bind to the membrane which 558	  
are influenced by the fatty acid composition of the lipid bilayers (50, 51). Gene ontology analysis 559	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indicated that proteins associated with protein folding at the membrane were overrepresented 560	  
following EPA incorporation. There is experimental evidence that a number of the proteins identified 561	  
with this process interact, as probed by the STRING database. Furthermore, analysis of ribosomal 562	  
proteins indicated a small but significant shift of ribosomal proteins towards the membrane fraction in 563	  
EPA treated cells. Since the endoplasmic reticulum is a membranous structure these data suggest that 564	  
EPA is increasing the content of ribosomes at the ER. This shift in ribosomes towards the ER could 565	  
lead to improved fidelity of protein production as the ER is key to protein quality control (15). We 566	  
propose a mechanism in which protein folding is enhanced, thereby enhancing the fidelity with which 567	  
proteins are synthesised thereby reducing protein breakdown leading to increased protein accretion. 568	  
Further experimental work is needed to confirm this hypothesis since mis-folded proteins tend to be 569	  
degraded by the ubiquitin-proteasome system (9) and our data indicated that global ubiquitination was 570	  
not reduced by EPA. By comparison, DHA caused a striking reduction in the abundance of a number 571	  
of ribosomal proteins with the membrane fraction. If future work confirms that total ribosomal content 572	  
is unchanged with these conditions then these data would indicate an increase in cytosolic ribosomes. 573	  
This differential shift in ribosomal compartmentalisation may indicate a shift in protein expression 574	  
profiles. Proteins that enter the secretory pathways or integral membrane proteins are synthesised in 575	  
the ER while other proteins are translated in the cytosolic ribosome pool (41).  576	  
DHA also altered the abundance of proteins involved in ATP coupled proton transport and acetyl-577	  
CoA metabolism. The proteins identified with ATP synthesis coupled transport were mainly 578	  
downregulated proteins in the ATP synthase complex. This would be expected to manifest as a 579	  
reduced ability to generate ATP yet no changes were observed in ATP synthase dependent oxygen 580	  
consumption. The effects of DHA may not have been severe enough to observe at basal levels. 581	  
Although maximal respiration is measured during the mito stress test, it is induced by uncoupling so 582	  
may not be indicative of changes in ATP synthesis. Previous studies have observed that omega-3 fatty 583	  
acids can alter mitochondrial function, altering ADP kinetics without altering maximal respiration 584	  
(20). It remains to be seen if this reduction in ATP synthase proteins would alter the mitochondrial 585	  
response to cellular stress or changing substrate availability. 586	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In summary, we demonstrate that EPA and DHA display divergent metabolic activities in a skeletal 587	  
muscle cell line, which may be partially mediated by differential remodelling of the lipidome. We 588	  
speculate that the remodelling of the membrane-associated proteome is secondary to the changes 589	  
observed in the saturation profile of the membrane-associated phospholipid species. Whilst the 590	  
proteomic data did not reveal a mechanism for the effects of EPA on glucose uptake, our data support 591	  
the proof of concept that a redistribution of the proteome may be responsible. Gene ontology analysis 592	  
of the proteomic data indicate that the mechanism of action of EPA on protein metabolism may be 593	  
driven by an improved fidelity with which proteins are synthesised. Based on the shifts in ribosomal 594	  
proteins found in the membrane fractions future work should determine if EPA and DHA alter the 595	  
transcript profiles in various ribosomal fractions. 596	  
  597	  
	   26	  
References 598	  
1.	   Aas	  V,	  Rokling-­‐Andersen	  MH,	  Kase	  ET,	  Thoresen	  GH,	  and	  Rustan	  AC.	  Eicosapentaenoic	  acid	  599	  
(20:5	  n-­‐3)	  increases	  fatty	  acid	  and	  glucose	  uptake	  in	  cultured	  human	  skeletal	  muscle	  cells.	  J	  Lipid	  Res	  600	  
47:	  366-­‐374,	  2006.	  601	  
2.	   Achard	  F,	  Benistant	  C,	  and	  Lagarde	  M.	  Interconversions	  and	  distinct	  metabolic	  fate	  of	  602	  
eicosapentaenoic,	  docosapentaenoic	  and	  docosahexaenoic	  acids	  in	  bovine	  aortic	  endothelial	  cells.	  603	  
Biochim	  Biophys	  Acta	  1255:	  260-­‐266,	  1995.	  604	  
3.	   Akiba	  S,	  Murata	  T,	  Kitatani	  K,	  and	  Sato	  T.	  Involvement	  of	  lipoxygenase	  pathway	  in	  605	  
docosapentaenoic	  acid-­‐induced	  inhibition	  of	  platelet	  aggregation.	  Biol	  Pharm	  Bull	  23:	  1293-­‐1297,	  606	  
2000.	  607	  
4.	   Akinkuolie	  AO,	  Ngwa	  JS,	  Meigs	  JB,	  and	  Djousse	  L.	  Omega-­‐3	  polyunsaturated	  fatty	  acid	  and	  608	  
insulin	  sensitivity:	  a	  meta-­‐analysis	  of	  randomized	  controlled	  trials.	  Clin	  Nutr	  30:	  702-­‐707,	  2011.	  609	  
5.	   Alexander	  JW,	  Saito	  H,	  Trocki	  O,	  and	  Ogle	  CK.	  The	  importance	  of	  lipid	  type	  in	  the	  diet	  after	  610	  
burn	  injury.	  Ann	  Surg	  204:	  1-­‐8,	  1986.	  611	  
6.	   Andersson	  A,	  Nalsen	  C,	  Tengblad	  S,	  and	  Vessby	  B.	  Fatty	  acid	  composition	  of	  skeletal	  muscle	  612	  
reflects	  dietary	  fat	  composition	  in	  humans.	  Am	  J	  Clin	  Nutr	  76:	  1222-­‐1229,	  2002.	  613	  
7.	   Browning	  LM,	  Walker	  CG,	  Mander	  AP,	  West	  AL,	  Gambell	  J,	  Madden	  J,	  Calder	  PC,	  and	  Jebb	  614	  
SA.	  Compared	  with	  daily,	  weekly	  n-­‐3	  PUFA	  intake	  affects	  the	  incorporation	  of	  eicosapentaenoic	  acid	  615	  
and	  docosahexaenoic	  acid	  into	  platelets	  and	  mononuclear	  cells	  in	  humans.	  J	  Nutr	  144:	  667-­‐672,	  616	  
2014.	  617	  
8.	   Burdge	  GC,	  and	  Calder	  PC.	  Introduction	  to	  fatty	  acids	  and	  lipids.	  World	  Rev	  Nutr	  Diet	  112:	  1-­‐618	  
16,	  2015.	  619	  
9.	   Ciechanover	  A.	  Intracellular	  protein	  degradation:	  from	  a	  vague	  idea	  thru	  the	  lysosome	  and	  620	  
the	  ubiquitin-­‐proteasome	  system	  and	  onto	  human	  diseases	  and	  drug	  targeting.	  Cell	  Death	  Differ	  12:	  621	  
1178-­‐1190,	  2005.	  622	  
10.	   Cox	  J,	  and	  Mann	  M.	  MaxQuant	  enables	  high	  peptide	  identification	  rates,	  individualized	  623	  
p.p.b.-­‐range	  mass	  accuracies	  and	  proteome-­‐wide	  protein	  quantification.	  Nat	  Biotechnol	  26:	  1367-­‐624	  
1372,	  2008.	  625	  
11.	   Cox	  J,	  Neuhauser	  N,	  Michalski	  A,	  Scheltema	  RA,	  Olsen	  JV,	  and	  Mann	  M.	  Andromeda:	  a	  626	  
peptide	  search	  engine	  integrated	  into	  the	  MaxQuant	  environment.	  J	  Proteome	  Res	  10:	  1794-­‐1805,	  627	  
2011.	  628	  
12.	   Da	  Boit	  M,	  Sibson	  R,	  Sivasubramaniam	  S,	  Meakin	  JR,	  Greig	  CA,	  Aspden	  RM,	  Thies	  F,	  629	  
Jeromson	  S,	  Hamilton	  DL,	  Speakman	  JR,	  Hambly	  C,	  Mangoni	  AA,	  Preston	  T,	  and	  Gray	  SR.	  Sex	  630	  
differences	  in	  the	  effect	  of	  fish	  oil	  supplementation	  on	  the	  adaptive	  response	  to	  resistance	  exercise	  631	  
training	  in	  older	  people:	  a	  randomized	  control	  trial.	  Am	  J	  Clin	  Nutr	  2016.	  632	  
13.	   Dangardt	  F,	  Chen	  Y,	  Gronowitz	  E,	  Dahlgren	  J,	  Friberg	  P,	  and	  Strandvik	  B.	  High	  physiological	  633	  
omega-­‐3	  Fatty	  Acid	  supplementation	  affects	  muscle	  Fatty	  Acid	  composition	  and	  glucose	  and	  insulin	  634	  
homeostasis	  in	  obese	  adolescents.	  J	  Nutr	  Metab	  2012:	  395757,	  2012.	  635	  
14.	   Di	  Girolamo	  FG,	  Situlin	  R,	  Mazzucco	  S,	  Valentini	  R,	  Toigo	  G,	  and	  Biolo	  G.	  Omega-­‐3	  fatty	  636	  
acids	  and	  protein	  metabolism:	  enhancement	  of	  anabolic	  interventions	  for	  sarcopenia.	  Curr	  Opin	  Clin	  637	  
Nutr	  Metab	  Care	  17:	  145-­‐150,	  2014.	  638	  
15.	   Ellgaard	  L,	  and	  Helenius	  A.	  Quality	  control	  in	  the	  endoplasmic	  reticulum.	  Nat	  Rev	  Mol	  Cell	  639	  
Biol	  4:	  181-­‐191,	  2003.	  640	  
16.	   Findlay	  JA,	  Hamilton	  DL,	  and	  Ashford	  ML.	  BACE1	  activity	  impairs	  neuronal	  glucose	  641	  
oxidation:	  rescue	  by	  beta-­‐hydroxybutyrate	  and	  lipoic	  acid.	  Front	  Cell	  Neurosci	  9:	  382,	  2015.	  642	  
17.	   Folch	  J,	  Lees	  M,	  and	  Sloane	  Stanley	  GH.	  A	  simple	  method	  for	  the	  isolation	  and	  purification	  643	  
of	  total	  lipides	  from	  animal	  tissues.	  J	  Biol	  Chem	  226:	  497-­‐509,	  1957.	  644	  
18.	   Franekova	  V,	  Angin	  Y,	  Hoebers	  NT,	  Coumans	  WA,	  Simons	  PJ,	  Glatz	  JF,	  Luiken	  JJ,	  and	  Larsen	  645	  
TS.	  Marine	  omega-­‐3	  fatty	  acids	  prevent	  myocardial	  insulin	  resistance	  and	  metabolic	  remodeling	  as	  646	  
induced	  experimentally	  by	  high	  insulin	  exposure.	  Am	  J	  Physiol	  Cell	  Physiol	  308:	  C297-­‐307,	  2015.	  647	  
	   27	  
19.	   Gregory	  MK,	  Gibson	  RA,	  Cook-­‐Johnson	  RJ,	  Cleland	  LG,	  and	  James	  MJ.	  Elongase	  reactions	  as	  648	  
control	  points	  in	  long-­‐chain	  polyunsaturated	  fatty	  acid	  synthesis.	  PLoS	  One	  6:	  e29662,	  2011.	  649	  
20.	   Herbst	  EA,	  Paglialunga	  S,	  Gerling	  C,	  Whitfield	  J,	  Mukai	  K,	  Chabowski	  A,	  Heigenhauser	  GJ,	  650	  
Spriet	  LL,	  and	  Holloway	  GP.	  Omega-­‐3	  supplementation	  alters	  mitochondrial	  membrane	  composition	  651	  
and	  respiration	  kinetics	  in	  human	  skeletal	  muscle.	  J	  Physiol	  592:	  1341-­‐1352,	  2014.	  652	  
21.	   Hessvik	  NP,	  Bakke	  SS,	  Fredriksson	  K,	  Boekschoten	  MV,	  Fjorkenstad	  A,	  Koster	  G,	  Hesselink	  653	  
MK,	  Kersten	  S,	  Kase	  ET,	  Rustan	  AC,	  and	  Thoresen	  GH.	  Metabolic	  switching	  of	  human	  myotubes	  is	  654	  
improved	  by	  n-­‐3	  fatty	  acids.	  J	  Lipid	  Res	  51:	  2090-­‐2104,	  2010.	  655	  
22.	   Huang	  F,	  Wei	  H,	  Luo	  H,	  Jiang	  S,	  and	  Peng	  J.	  EPA	  inhibits	  the	  inhibitor	  of	  kappaBalpha	  656	  
(IkappaBalpha)/NF-­‐kappaB/muscle	  RING	  finger	  1	  pathway	  in	  C2C12	  myotubes	  in	  a	  PPARgamma-­‐657	  
dependent	  manner.	  Br	  J	  Nutr	  105:	  348-­‐356,	  2011.	  658	  
23.	   Jucker	  BM,	  Cline	  GW,	  Barucci	  N,	  and	  Shulman	  GI.	  Differential	  effects	  of	  safflower	  oil	  versus	  659	  
fish	  oil	  feeding	  on	  insulin-­‐stimulated	  glycogen	  synthesis,	  glycolysis,	  and	  pyruvate	  dehydrogenase	  flux	  660	  
in	  skeletal	  muscle:	  a	  13C	  nuclear	  magnetic	  resonance	  study.	  Diabetes	  48:	  134-­‐140,	  1999.	  661	  
24.	   Kamolrat	  T,	  and	  Gray	  SR.	  The	  effect	  of	  eicosapentaenoic	  and	  docosahexaenoic	  acid	  on	  662	  
protein	  synthesis	  and	  breakdown	  in	  murine	  C2C12	  myotubes.	  Biochem	  Biophys	  Res	  Commun	  432:	  663	  
593-­‐598,	  2013.	  664	  
25.	   Kanayasu-­‐Toyoda	  T,	  Morita	  I,	  and	  Murota	  S.	  Docosapentaenoic	  acid	  (22:5,	  n-­‐3),	  an	  665	  
elongation	  metabolite	  of	  eicosapentaenoic	  acid	  (20:5,	  n-­‐3),	  is	  a	  potent	  stimulator	  of	  endothelial	  cell	  666	  
migration	  on	  pretreatment	  in	  vitro.	  Prostaglandins	  Leukot	  Essent	  Fatty	  Acids	  54:	  319-­‐325,	  1996.	  667	  
26.	   Kaur	  G,	  Sinclair	  AJ,	  Cameron-­‐Smith	  D,	  Barr	  DP,	  Molero-­‐Navajas	  JC,	  and	  Konstantopoulos	  N.	  668	  
Docosapentaenoic	  acid	  (22:5n-­‐3)	  down-­‐regulates	  the	  expression	  of	  genes	  involved	  in	  fat	  synthesis	  in	  669	  
liver	  cells.	  Prostaglandins	  Leukot	  Essent	  Fatty	  Acids	  85:	  155-­‐161,	  2011.	  670	  
27.	   Lamaziere	  A,	  Wolf	  C,	  Barbe	  U,	  Bausero	  P,	  and	  Visioli	  F.	  Lipidomics	  of	  hepatic	  lipogenesis	  671	  
inhibition	  by	  omega	  3	  fatty	  acids.	  Prostaglandins	  Leukot	  Essent	  Fatty	  Acids	  88:	  149-­‐154,	  2013.	  672	  
28.	   Lanza	  IR,	  Blachnio-­‐Zabielska	  A,	  Johnson	  ML,	  Schimke	  JM,	  Jakaitis	  DR,	  Lebrasseur	  NK,	  673	  
Jensen	  MD,	  Sreekumaran	  Nair	  K,	  and	  Zabielski	  P.	  Influence	  of	  fish	  oil	  on	  skeletal	  muscle	  674	  
mitochondrial	  energetics	  and	  lipid	  metabolites	  during	  high-­‐fat	  diet.	  Am	  J	  Physiol	  Endocrinol	  Metab	  675	  
304:	  E1391-­‐1403,	  2013.	  676	  
29.	   Magee	  P,	  Pearson	  S,	  Whittingham-­‐Dowd	  J,	  and	  Allen	  J.	  PPARgamma	  as	  a	  molecular	  target	  677	  
of	  EPA	  anti-­‐inflammatory	  activity	  during	  TNF-­‐alpha-­‐impaired	  skeletal	  muscle	  cell	  differentiation.	  J	  678	  
Nutr	  Biochem	  23:	  1440-­‐1448,	  2012.	  679	  
30.	   McGlory	  C,	  Galloway	  SD,	  Hamilton	  DL,	  McClintock	  C,	  Breen	  L,	  Dick	  JR,	  Bell	  JG,	  and	  Tipton	  680	  
KD.	  Temporal	  changes	  in	  human	  skeletal	  muscle	  and	  blood	  lipid	  composition	  with	  fish	  oil	  681	  
supplementation.	  Prostaglandins	  Leukot	  Essent	  Fatty	  Acids	  90:	  199-­‐206,	  2014.	  682	  
31.	   Mori	  TA,	  Burke	  V,	  Puddey	  IB,	  Watts	  GF,	  O'Neal	  DN,	  Best	  JD,	  and	  Beilin	  LJ.	  Purified	  683	  
eicosapentaenoic	  and	  docosahexaenoic	  acids	  have	  differential	  effects	  on	  serum	  lipids	  and	  684	  
lipoproteins,	  LDL	  particle	  size,	  glucose,	  and	  insulin	  in	  mildly	  hyperlipidemic	  men.	  Am	  J	  Clin	  Nutr	  71:	  685	  
1085-­‐1094,	  2000.	  686	  
32.	   Mori	  TA,	  Codde	  JP,	  Vandongen	  R,	  and	  Beilin	  LJ.	  New	  findings	  in	  the	  fatty	  acid	  composition	  687	  
of	  individual	  platelet	  phospholipids	  in	  man	  after	  dietary	  fish	  oil	  supplementation.	  Lipids	  22:	  744-­‐750,	  688	  
1987.	  689	  
33.	   Morisaki	  N,	  Kanzaki	  T,	  Fujiyama	  Y,	  Osawa	  I,	  Shirai	  K,	  Matsuoka	  N,	  Saito	  Y,	  and	  Yoshida	  S.	  690	  
Metabolism	  of	  n-­‐3	  polyunsaturated	  fatty	  acids	  and	  modification	  of	  phospholipids	  in	  cultured	  rabbit	  691	  
aortic	  smooth	  muscle	  cells.	  J	  Lipid	  Res	  26:	  930-­‐939,	  1985.	  692	  
34.	   Murphy	  RA,	  Mourtzakis	  M,	  and	  Mazurak	  VC.	  n-­‐3	  polyunsaturated	  fatty	  acids:	  the	  potential	  693	  
role	  for	  supplementation	  in	  cancer.	  Curr	  Opin	  Clin	  Nutr	  Metab	  Care	  15:	  246-­‐251,	  2012.	  694	  
35.	   Neschen	  S,	  Morino	  K,	  Dong	  J,	  Wang-­‐Fischer	  Y,	  Cline	  GW,	  Romanelli	  AJ,	  Rossbacher	  JC,	  695	  
Moore	  IK,	  Regittnig	  W,	  Munoz	  DS,	  Kim	  JH,	  and	  Shulman	  GI.	  n-­‐3	  Fatty	  acids	  preserve	  insulin	  696	  
sensitivity	  in	  vivo	  in	  a	  peroxisome	  proliferator-­‐activated	  receptor-­‐alpha-­‐dependent	  manner.	  697	  
Diabetes	  56:	  1034-­‐1041,	  2007.	  698	  
	   28	  
36.	   Norris	  PC,	  and	  Dennis	  EA.	  Omega-­‐3	  fatty	  acids	  cause	  dramatic	  changes	  in	  TLR4	  and	  699	  
purinergic	  eicosanoid	  signaling.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  109:	  8517-­‐8522,	  2012.	  700	  
37.	   Oh	  DY,	  Talukdar	  S,	  Bae	  EJ,	  Imamura	  T,	  Morinaga	  H,	  Fan	  W,	  Li	  P,	  Lu	  WJ,	  Watkins	  SM,	  and	  701	  
Olefsky	  JM.	  GPR120	  is	  an	  omega-­‐3	  fatty	  acid	  receptor	  mediating	  potent	  anti-­‐inflammatory	  and	  702	  
insulin-­‐sensitizing	  effects.	  Cell	  142:	  687-­‐698,	  2010.	  703	  
38.	   Ong	  SE,	  Blagoev	  B,	  Kratchmarova	  I,	  Kristensen	  DB,	  Steen	  H,	  Pandey	  A,	  and	  Mann	  M.	  Stable	  704	  
isotope	  labeling	  by	  amino	  acids	  in	  cell	  culture,	  SILAC,	  as	  a	  simple	  and	  accurate	  approach	  to	  705	  
expression	  proteomics.	  Mol	  Cell	  Proteomics	  1:	  376-­‐386,	  2002.	  706	  
39.	   Ries	  A,	  Trottenberg	  P,	  Elsner	  F,	  Stiel	  S,	  Haugen	  D,	  Kaasa	  S,	  and	  Radbruch	  L.	  A	  systematic	  707	  
review	  on	  the	  role	  of	  fish	  oil	  for	  the	  treatment	  of	  cachexia	  in	  advanced	  cancer:	  an	  EPCRC	  cachexia	  708	  
guidelines	  project.	  Palliative	  medicine	  26:	  294-­‐304,	  2012.	  709	  
40.	   Rodacki	  CL,	  Rodacki	  AL,	  Pereira	  G,	  Naliwaiko	  K,	  Coelho	  I,	  Pequito	  D,	  and	  Fernandes	  LC.	  710	  
Fish-­‐oil	  supplementation	  enhances	  the	  effects	  of	  strength	  training	  in	  elderly	  women.	  Am	  J	  Clin	  Nutr	  711	  
95:	  428-­‐436,	  2012.	  712	  
41.	   Ron	  D.	  Translational	  control	  in	  the	  endoplasmic	  reticulum	  stress	  response.	  The	  Journal	  of	  713	  
Clinical	  Investigation	  110:	  1383-­‐1388,	  2002.	  714	  
42.	   Sjovall	  P,	  Rossmeisl	  M,	  Hanrieder	  J,	  Kuda	  O,	  Kopecky	  J,	  and	  Bryhn	  M.	  Dietary	  uptake	  of	  715	  
omega-­‐3	  fatty	  acids	  in	  mouse	  tissue	  studied	  by	  time-­‐of-­‐flight	  secondary	  ion	  mass	  spectrometry	  (TOF-­‐716	  
SIMS).	  Anal	  Bioanal	  Chem	  407:	  5101-­‐5111,	  2015.	  717	  
43.	   Smith	  GI,	  Atherton	  P,	  Reeds	  DN,	  Mohammed	  BS,	  Rankin	  D,	  Rennie	  MJ,	  and	  Mittendorfer	  B.	  718	  
Dietary	  omega-­‐3	  fatty	  acid	  supplementation	  increases	  the	  rate	  of	  muscle	  protein	  synthesis	  in	  older	  719	  
adults:	  a	  randomized	  controlled	  trial.	  Am	  J	  Clin	  Nutr	  93:	  402-­‐412,	  2011.	  720	  
44.	   Smith	  GI,	  Atherton	  P,	  Reeds	  DN,	  Mohammed	  BS,	  Rankin	  D,	  Rennie	  MJ,	  and	  Mittendorfer	  B.	  721	  
Omega-­‐3	  polyunsaturated	  fatty	  acids	  augment	  the	  muscle	  protein	  anabolic	  response	  to	  722	  
hyperinsulinaemia-­‐hyperaminoacidaemia	  in	  healthy	  young	  and	  middle-­‐aged	  men	  and	  women.	  Clin	  723	  
Sci	  (Lond)	  121:	  267-­‐278,	  2011.	  724	  
45.	   Smith	  GI,	  Julliand	  S,	  Reeds	  DN,	  Sinacore	  DR,	  Klein	  S,	  and	  Mittendorfer	  B.	  Fish	  oil-­‐derived	  n-­‐725	  
3	  PUFA	  therapy	  increases	  muscle	  mass	  and	  function	  in	  healthy	  older	  adults.	  Am	  J	  Clin	  Nutr	  102:	  115-­‐726	  
122,	  2015.	  727	  
46.	   Stephens	  FB,	  Mendis	  B,	  Shannon	  CE,	  Cooper	  S,	  Ortori	  CA,	  Barrett	  DA,	  Mansell	  P,	  and	  728	  
Tsintzas	  K.	  Fish	  oil	  omega-­‐3	  fatty	  acids	  partially	  prevent	  lipid-­‐induced	  insulin	  resistance	  in	  human	  729	  
skeletal	  muscle	  without	  limiting	  acylcarnitine	  accumulation.	  Clin	  Sci	  (Lond)	  127:	  315-­‐322,	  2014.	  730	  
47.	   Storlien	  LH,	  Jenkins	  AB,	  Chisholm	  DJ,	  Pascoe	  WS,	  Khouri	  S,	  and	  Kraegen	  EW.	  Influence	  of	  731	  
dietary	  fat	  composition	  on	  development	  of	  insulin	  resistance	  in	  rats.	  Relationship	  to	  muscle	  732	  
triglyceride	  and	  omega-­‐3	  fatty	  acids	  in	  muscle	  phospholipid.	  Diabetes	  40:	  280-­‐289,	  1991.	  733	  
48.	   Storlien	  LH,	  Kraegen	  EW,	  Chisholm	  DJ,	  Ford	  GL,	  Bruce	  DG,	  and	  Pascoe	  WS.	  Fish	  oil	  prevents	  734	  
insulin	  resistance	  induced	  by	  high-­‐fat	  feeding	  in	  rats.	  Science	  237:	  885-­‐888,	  1987.	  735	  
49.	   Tripathi	  R,	  Benz	  N,	  Culleton	  B,	  Trouve	  P,	  and	  Ferec	  C.	  Biophysical	  characterisation	  of	  736	  
calumenin	  as	  a	  charged	  F508del-­‐CFTR	  folding	  modulator.	  PLoS	  One	  9:	  e104970,	  2014.	  737	  
50.	   Vance	  JE.	  Phospholipid	  synthesis	  and	  transport	  in	  mammalian	  cells.	  Traffic	  16:	  1-­‐18,	  2015.	  738	  
51.	   Vance	  JE,	  and	  Tasseva	  G.	  Formation	  and	  function	  of	  phosphatidylserine	  and	  739	  
phosphatidylethanolamine	  in	  mammalian	  cells.	  Biochim	  Biophys	  Acta	  1831:	  543-­‐554,	  2013.	  740	  
52.	   Wang	  Y,	  Lin	  QW,	  Zheng	  PP,	  Zhang	  JS,	  and	  Huang	  FR.	  DHA	  inhibits	  protein	  degradation	  more	  741	  
efficiently	  than	  EPA	  by	  regulating	  the	  PPARgamma/NFkappaB	  pathway	  in	  C2C12	  myotubes.	  Biomed	  742	  
Res	  Int	  2013:	  318981,	  2013.	  743	  
53.	   Woodman	  RJ,	  Mori	  TA,	  Burke	  V,	  Puddey	  IB,	  Watts	  GF,	  Best	  JD,	  and	  Beilin	  LJ.	  744	  
Docosahexaenoic	  acid	  but	  not	  eicosapentaenoic	  acid	  increases	  LDL	  particle	  size	  in	  treated	  745	  
hypertensive	  type	  2	  diabetic	  patients.	  Diabetes	  Care	  26:	  253,	  2003.	  746	  
54.	   Yea	  K,	  Kim	  J,	  Yoon	  JH,	  Kwon	  T,	  Kim	  JH,	  Lee	  BD,	  Lee	  HJ,	  Lee	  SJ,	  Kim	  JI,	  Lee	  TG,	  Baek	  MC,	  Park	  747	  
HS,	  Park	  KS,	  Ohba	  M,	  Suh	  PG,	  and	  Ryu	  SH.	  Lysophosphatidylcholine	  activates	  adipocyte	  glucose	  748	  
	   29	  
uptake	  and	  lowers	  blood	  glucose	  levels	  in	  murine	  models	  of	  diabetes.	  J	  Biol	  Chem	  284:	  33833-­‐33840,	  749	  
2009.	  750	  
55.	   You	  JS,	  Park	  MN,	  Song	  W,	  and	  Lee	  YS.	  Dietary	  fish	  oil	  alleviates	  soleus	  atrophy	  during	  751	  
immobilization	  in	  association	  with	  Akt	  signaling	  to	  p70s6k	  and	  E3	  ubiquitin	  ligases	  in	  rats.	  Appl	  752	  
Physiol	  Nutr	  Metab	  35:	  310-­‐318,	  2010.	  753	  
 754	  
ACKNOWLEDGEMENTS 755	  
This work was funded by a University of Stirling capital investment award (DLH) and Society for 756	  
Endocrinology and American College of Sports Medicine early career awards (DLH). The financial 757	  
support of Highlands and Islands Enterprise, Scottish Funding Council and European Regional 758	  
Development Fund is gratefully acknowledged (IM, MKD and PDW). We acknowledge Liz 759	  
Mackinlay for assistance with the FAME analysis. 760	  
  761	  
	   30	  
Figure Legends 762	  
Figure 1. EPA and DHA enhance n-3 content to a similar degree. C2C12 myotubes were incubated 763	  
in either fatty acid free 2% BSA or fatty acid free 2% BSA pre-conjugated to 50 µM EPA or 50 µM 764	  
DHA for 72hrs. Fatty acid analysis was carried out by FAME analysis (n=4 in duplicate) and data are 765	  
presented as % change from BSA control grouped by fatty acid species; SFA – saturated fatty acids, 766	  
MUFA – monounsaturated fatty acids, n-9 PUFA – omega-9 polyunsaturated fatty acids, n-6 PUFA – 767	  
omega-6 polyunsaturated fatty acids, n-3 PUFA – omega-3 polyunsaturated fatty acids. 768	  
Figure 2. EPA and DHA have differential effects on C2C12 glucose uptake independently of 769	  
changes in PKB Thr308 phosphorylation or GLUT1/4 and Hexokinase1/2 expression. Glucose 770	  
uptake was determined using a radiolabelled 2 Deoxy-glucose uptake assay (n=6 in duplicate) (A) and 771	  
PKB Thr308 phosphorylation (n=4 in duplicate) (B) was determined using SDS-PAGE and phospho-772	  
specific antibodies, the signal for which was normalised to t-PKB expression (representative blots are 773	  
inset). GLUT1/4 expression (C) were normalised to t-eEF2 whilst Hexokinase1/2 expression (D) were 774	  
normalised to α-tubulin. Bars not connected by the same letter are significantly different from each 775	  
other (p<0.05). 776	  
Figure 3. EPA and DHA treatment do not modulate mitochondrial function or mitochondrial 777	  
protein expression. C2C12 myotubes were incubated in either fatty acid free 2% BSA or fatty acid 778	  
free 2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 48hrs. One set of myotubes was 779	  
exposed to a mitochondrial stress test in the SeaHorse XFA and oxygen consumption was assessed 780	  
(A). A parallel set of myotubes were collected for western blot analysis of mitochondrial protein 781	  
expression with the mito-blot panel (B). Representative blots are shown in (C). 782	  
Figure 4. EPA enhances protein accretion through a reduction in protein breakdown. A) Protein 783	  
synthesis was measured by a L-[2,4,3H] phenylalanine incorporation assay following a 24 hr 784	  
incubation with n-3 fatty acids (n=5 in duplicate) B) protein breakdown was assessed by the release of 785	  
L-[2,4,3H] phenylalanine into culture media after 24hr treatment with  n-3 fatty acids (n=10, in 786	  
duplicate) C) total protein content was assessed after a 72hr incubation with EPA or DHA (n=5, in 787	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duplicate) D) Phosphorylation of proteins within the mTOR signalling pathway were assessed by 788	  
western blotting after a 24 hr incubation with n-3 fatty acids (n=3 in duplicate) E) ubiquitination of 789	  
proteins were assessed by western blotting after a 24hr incubation with fatty acids (n=3 in duplicate). 790	  
# indicates significantly different from Veh and DHA, * indicates significantly different from 791	  
corresponding control condition (p<0.05). 792	  
Figure 5. Complete fatty acid profiles reveal a number of fatty acids differentially regulated by 793	  
EPA and DHA. C2C12 myotubes were incubated in either fatty acid free 2% BSA or fatty acid free 794	  
2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 72hrs (n=4 in duplicate). Cells were 795	  
pelleted and washed 3x using PBS with 2% fatty acid free BSA. Fatty acid analysis was carried out by 796	  
FAME analysis. The fold change was determined from the BSA control condition and logged (log2). 797	  
ND indicates non detectable, * indicates significant difference between EPA vs DHA (p<0.05).  798	  
Figure 6. Global lipidomic analysis characterises shifts in lipid composition of C2C12 myotubes. 799	  
Principal component analysis (PCA) scores plots of lipid profiles generated by LC-MS in (A) positive 800	  
ion and (B) negative ion modes. Cultured cells were incubated with either fatty acid free 2% BSA 801	  
(green circles), fatty acid free 2% BSA pre-conjugated to 50 µM EPA (red triangles) or 50 µM DHA 802	  
(blue squares) for 72hrs. Global lipidomic analysis was performed on the cells and the data sets were 803	  
subjected to PCA with Pareto scaling. Each point represents a single cell sample (n=6). The PCA 804	  
revealed that the control, EPA and DHA groups could be discriminated on the basis of their lipid 805	  
profiles. The control cells were found to cluster in one area of the scores plot whilst cells treated with 806	  
EPA or DHA appeared in regions away from the controls indicating that were alterations in their lipid 807	  
composition as a result of the fatty acid treatments.  808	  
Figure 7. Lipidomic profiling reveals cellular lipid species containing EPA, DPA and DHA. 809	  
Positive ion orthogonal partial least-squares discriminant analysis (OPLS-DA) for (A) BSA vs DHA 810	  
and (B) BSA vs EPA (n=6). Green circles indicate BSA treated C2C12 myotubes; blue squares indicate 811	  
DHA treated C2C12 myotubes and red triangles indicate EPA treated C2C12 myotubes. The OPLS-DA 812	  
scores plots indicated that EPA and DHA groups had distinct lipid profiles compared to the controls. 813	  
In order to determine the lipids responsible for the inter-class differences associated S-plots of 814	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covariance versus the correlation were generated.	  Each point in the S-plots represents a lipid detected 815	  
in the LC-MS analysis with the lipids at the top and bottom of the plots showing the greatest changes. 816	  
The analysis revealed that there was a relative increase in the abundance of lipid species containing 817	  
20:5, 22:5 or 22:6 fatty acids in EPA and DHA treated cells respectively. 818	  
 819	  
Figure 8. Targeted phospholipid analysis indicates preferential incorporation of long chain 820	  
polyunsaturated fatty acids into specific phospholipid classes. C2C12 myotubes were solvent 821	  
extracted and molecular species of (A) phosphatidylcholine and (B) phosphatidylethanolamines were 822	  
detected by ESI-MS/MS in positive-ion mode by means of a precursor ion scan for m/z 184 and a 823	  
neutral loss scan of m/z 141 respectively. 824	  
Figure 9. Targeted phospholipid analysis presented as % abundance for PC, PE, LPC and LPE 825	  
species. C2C12 myotubes were solvent extracted and molecular species of (A) lyso-826	  
phosphatidylcholine, (B) phosphatidylcholine, (C) lyso-phosphatidylethanolamine and (D) 827	  
phosphatidylethanolamine were detected by ESI-MS/MS in positive-ion mode by means of a 828	  
precursor ion scan for m/z 184 and a neutral loss scan of m/z 141 respectively. Data are presented as 829	  
% abundance ± SEM. Bars not connected by the same letter are significantly different from one 830	  
another (p<0.05). 831	  
Figure 10. Membrane associated proteomics reveals protein folding machinery and ribosomal 832	  
proteins differentially shift to the membrane in response to EPA treatment. C2C12 myotubes were 833	  
incubated in SILAC media for 7 doublings followed by plating and differentiation for 72hrs in SILAC 834	  
differentiation media. Following differentiation myotubes were incubated in either fatty acid free 2% 835	  
BSA or fatty acid free 2% BSA pre-conjugated to 50 µM EPA or 50 µM DHA for 72hrs (n=3 in 836	  
duplicate). Cells were collected and fractionated, the membrane fraction was then submitted to 837	  
proteomics analysis. (A) Venne diagram illustrating the number of proteins found to be changed in the 838	  
membrane fraction in response to EPA/DHA. (B) String diagram illustrating the interactions between 839	  
the proteins identified from the GO analysis as being involved in ‘protein folding.’ (C) Fold change in 840	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ribosomal proteins in the membrane fraction in response to EPA/DHA. * indicates a significant fold 841	  
change from control (p<0.05). All differences between EPA and DHA were significant. 842	  
 843	  
 844	  
 845	  
 846	  
 847	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